Daily subcutaneous bulevirtide (BLV) 2 mg has been approved as first-line treatment for chronic hepatitis D (CHD), but long-term real-world adherence data are limited. We assessed adherence rates during BLV therapy and their impact on treatment response. HERACLIS_BLV_D study (NCT05928000) included adult CHD patients initiating BLV 2 mg/day and followed in routine clinical practice. Virological response (VR) was defined as HDV RNA < 57.5 IU/mL or decline > 2 log10 and biochemical response (BR) as normal ALT (≤ 40 IU/L). Adherence was evaluated through the national prescription system based on executed monthly BLV prescriptions. Treatment discontinuation was defined as no executed BLV prescription for > 3 months at the end of follow-up. Seventy-six patients were included. VR/BR rates were 73%/71% at 12 and 93%/74% at 24 months. Thirteen (17%) patients discontinued BLV (none due to adverse events); 6%-7% per year. Mean adherence among treated patients was 98% ± 6% in 1st year declining to 93% ± 13% in 2nd and 91% ± 17% in 3rd year (p ≤ 0.010). No baseline characteristic was associated with poor (< 90%) or good (≥ 90%) adherence to BLV therapy. Patients with poor vs. good adherence had lower VR rates (1st year: 33% vs. 77%, p = 0.038; 2nd year: 60% vs. 97%, p = 0.030). In conclusion, in clinical practice, < 10% of CHD patients discontinue BLV therapy annually. Adherence is excellent in the first year and remains > 90% until the third year although gradually declines. Poor (< 90%) adherence cannot be predicted but adversely affects the VR rates emphasizing the need for strategies to support long-term treatment retention.

Sustained virological response (SVR) improves prognosis in patients with chronic hepatitis C virus (HCV) with compensated cirrhosis, but whether a similar benefit can be obtained in decompensated patients is controversial. We studied the association between SVR and liver-related events (LREs) in patients with decompensated HCV cirrhosis. We included patients with decompensated HCV cirrhosis (Child-Turcotte-Pugh [CTP] ≥7 and/or history of decompensation) treated with direct-acting antivirals. The association between SVR and LREs, and between SVR-related change in Model for End-stage Liver Disease (MELD) score and LREs were assessed. In total, 914 patients were included, with a median age of 54.7 years; 45% had alcohol use disorder, 87% CTP-B, and the median MELD score was 12.1. SVR was achieved in 834 patients (91.2%), with a median follow-up of 28 months. The 3-year cumulative incidence of LREs was 47.5% in patients with SVR compared with 58.6% in those without (P < .001). Findings were consistent in multivariable analysis (adjusted hazard ratio [aHR], 0.692; P = .011). SVR was associated with a reduced risk of LREs in patients with a pretreatment MELD <15 (44.4% vs 57.6%; aHR, 0.601; P = .004), but not among patients with MELD ≥15 (62.8% vs 58.9%; aHR, 0.936; P = .801). Among patients with SVR, a ≥2-point decrease in MELD was observed in 23.4% and was not associated with a reduced risk of LREs (52.1% vs 50.7%; P = .473). Findings were consistent in multivariable analysis (aHR, 0.730; P = .122), and in patients with a pretreatment MELD score ≥15. SVR was associated with a reduced risk of LREs in patients with decompensated HCV cirrhosis with a MELD score <15, whereas no clinical benefit was observed in those with higher MELD scores despite an SVR-associated MELD decrease.

The role of direct-acting antivirals (DAAs) in patients with hepatocellular carcinoma (HCC) remains uncertain due to conflicting data on virologic efficacy and long-term outcomes. This meta-analysis investigated studies reporting the sustained virologic response (SVR), recurrence, and overall survival in patients with HCC treated with DAAs. Eighty-eight studies were included, comprising 8,839 patients with HCC who were treated with DAAs. The pooled SVR rate in patients with HCC was 89% (95% confidence interval [CI], 87% to 91%). However, the SVR varied significantly depending on tumor viability; patients with non-viable HCC had the highest SVR (91%), followed by those with mixed (88%) and viable HCC (84%). The SVR was significantly lower in the HCC group than in the non-HCC group (risk ratio [RR], 0.95; 95% CI, 0.92 to 0.98). In 28 studies reporting on recurrence outcomes, patients with HCC who were treated with DAAs had a 40% lower recurrence risk than non-DAA-treated patients (RR, 0.60; 95% CI, 0.49 to 0.75). Pooled analyses of adjusted estimates showed that DAA treatment was independently associated with reduced recurrence (hazard ratio [HR], 0.47; 95% CI, 0.32 to 0.70) and all-cause mortality (HR, 0.40; 95% CI, 0.31 to 0.51). An SVR was linked to an improved prognosis, with lower recurrence (HR, 0.43; 95% CI, 0.31 to 0.61) and mortality (HR, 0.41; 95% CI, 0.14 to 1.24) risks. DAAs are effective in patients with HCC. Despite slightly lower SVR rates than in patients without HCC, the overall benefits support the use of antiviral therapy in patients with HCC.

A precision randomized trial of hepatitis C treatment support among people who inject drugs in India: The STOP-C Trial.

Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections are major public health issues throughout the world. In resource-limited areas, successful treatment of HCV/HIV coinfection frequently faces challenges, particularly restricted access to drugs and poor treatment compliance. However, data comparing single-tablet regimen (STR) versus multi-tablet regimen (MTR) direct-acting antiviral (DAA) strategies, specifically focusing on pill burden, remain scarce in such settings. This single-center, retrospective cohort study enrolled patients with HCV/HIV coinfection between April 2023 and October 2025. All patients received DAA therapy in addition to the antiretroviral therapy (ART). Participants were divided into DAA STR (one pill daily) and DAA MTR (multiple pills daily) groups. The primary endpoint was sustained virologic response at least 12 weeks after completion of treatment (SVR). A total of 105 patients with HCV/HIV coinfection were enrolled. The overall SVR rate was 96.2% (101/105). The DAA STR group had a numerically higher SVR rate than the DAA MTR group (98.8% vs. 88.0%, P = 0.041); however, this comparison was confounded by genotype. In a sensitivity analysis limited to non-genotype 3b patients (n = 87), SVR rate was 98.8% in the DAA STR group and 85.7% in the DAA MTR group (P = 0.155). The DAA STR demonstrated a numerical advantage in achieving SVR in all subgroups stratified by sex, age, HCV infection route, baseline HCV RNA level, HCV genotype, and ART regimen. Univariate logistic regression identified DAA regimen was the only factor associated with SVR (OR 10.773, 95% CI 1.067-108.743); however, because only 4 participants failed to achieve SVR, this analysis was exploratory and the estimate was statistically unstable. In this real-world study, both DAA STR and DAA MTR achieved high overall SVR rates in HCV/HIV coinfection in a resource-limited setting. The simplified DAA STR was associated with a numerically higher SVR, but the comparison was confounded by the selective allocation of genotype 3b patients to DAA MTR. The observed difference between DAA STR and DAA MTR may reflect treatment selection practices and genotype distribution rather than an independent effect of regimen simplification. The simplified pill count-based strategy remains a practical option, but its advantage over MTR was confounded by genotype selection in this cohort. Our findings support the feasibility of both approaches and highlight the need for large, prospective, genotype-balanced comparative studies with integrated adherence monitoring.

To characterize HIV-1 molecular epidemiology and identify novel circulating recombinant forms (CRFs) among antiretroviral therapy (ART)-naïve heterosexuals in Yunnan, China, and evaluate their clinical impact. This study examined 636 HIV-1 pol sequences to analyze genetic diversity, pretreatment drug resistance (PDR), and transmission networks. Near full-length genomes were obtained to identify and characterize novel recombinants, with their evolutionary history inferred by Bayesian analysis. Co-receptor tropism was predicted, and the five-year clinical outcomes (including immune reconstitution and virologic response) of patients infected with the novel CRFs were compared. The most prevalent type identified was CRF08_BC, accounting for 50.16% of cases. The prevalence of drug resistance was 5.97% (38/636), with the K103N mutation being the most common. An analysis of transmission networks revealed that 52.2% (272/521) of clusters were associated with CRF07_BC and CRF08_BC. Two novel second-generation CRFs were identified: CRF190_0708, with an estimated time to the most recent common ancestor (tMRCA) of 1998.9, and CRF191_0708, with a more recent tMRCA ranging from 2009.5 to 2011.6. During the five-year follow-up period, viral rebound was observed in 7 patients in the CRF190_0708 group and in 1 patient in the CRF191_0708 group. Drug-resistance mutations (M184V and K103N) were detected in a subset of rebound cases in the CRF190_0708 group. This study identifies two novel HIV-1 recombinants, CRF190_0708 and CRF191_0708, highlighting ongoing viral evolution in Yunnan. Preliminary findings suggest possible clinical differences, warranting further investigation. Continued molecular surveillance is needed. The clinical study was registered at ClinicalTrials.gov under the identifier NCT03852849. The date of registration was March 22, 2019.

Interferon (IFN)-free direct-acting antivirals (DAAs) have significantly improved hepatitis C virus (HCV) elimination rates. However, new-onset or recurrence of hepatocellular carcinoma (HCC) remains common even after achieving sustained virological response (SVR). This study investigated the clinical significance and treatability of HCC recurrence patterns after SVR, which have not been fully explored yet. We retrospectively analyzed the risk factors for HCC development in 279 patients with HCV-associated chronic liver disease who achieved SVR with DAA therapy after July 2014. Twenty-eight patients with HCC recurrence after SVR were classified by the type of recurrence (intrahepatic metastasis, hypervascularization, and de novo). Correlation between tumor markers (alpha-fetoprotein and des-γ-carboxy prothrombin) at the time of previous HCC and at the time of recurrence was examined. Thirty-three patients (11.8%) developed HCC after SVR. Multivariate analysis revealed that a history of HCC was the only independent risk factor for HCC development after SVR (hazard ratio 14.4, P < 0.001). Among the 28 patients with HCC recurrence, intrahepatic metastasis was observed in eight (29%), hypervascularization in seven (25%), and de novo recurrence in six (21%) patients. At the time of recurrence, 27 patients (96%) had Barcelona clinic liver cancer stage 0/A disease. Curative treatment was possible in 27 patients (96%). HCC recurrence after SVR was detected early, regardless of the recurrence pattern, allowing for the selection of curative treatment. In the DAA era, HCC recurrence after SVR in patients with a history of HCC could be appropriately managed through strict follow-up.

Treatment options for chronic hepatitisD (CHD) are limited in patients who do not respond to recommended treatment with bulevirtide ± pegylated interferon. The use of REP 2139-Mg is anovel treatment option that has recently demonstrated efficacy and safety in phase2 trials and acompassionate access program that included three patients treated at the Vienna General Hospital with compensated advanced chronic liver disease and clinically significant portal hypertension (CSPH). Long-term outcome of CSPH patients treated with REP 2139-Mg is unknown; thus, surrogate endpoints are of interest in this population. In the 3 patients receiving REP 2139-Mg for 12 months at our center, we monitored the hepatic venous pressure gradient (HVPG) as the strongest prognostic surrogate biomarker in compensated cirrhosis at baseline, and after 3 and 12 months of treatment. The HVPG dynamics alongside additional liver function tests observed are summarized in this report and two out of three patients achieved undetectable hepatitis-D-virus(HDV)-RNA and low hepatitis B surface Antigen (HBsAg) following pronounced alanine aminotransferase (ALT) flares during REP 2139-Mg treatment. The first patient showed virologic non-response and no HVPG dynamics during treatment. The second patient developed jaundice upon treatment initiation, resulting in atransient increase in HVPG despite virologic response. The third patient achieved virologic response that was paralleled by sustained reductions in HVPG.

ABSTRACTAimWe examine the impact of interferon (IFN)‐based and IFN‐free treatment on the prognosis of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) sustained virological response (SVR).MethodsClinical information was collected on 311 cases of HCC after HCV‐SVR from 16 facilities affiliated with the Kyushu Liver Surgery Study Group. Clinical factors and the tumor microenvironment of HCC after SVR treatment with IFN‐based and IFN‐free treatments were analyzed.ResultsNo statistically significant differences were observed in the recurrence rate and overall survival (OS) between the two groups. Propensity score–matched analysis similarly showed no statistically significant differences in recurrence and OS. In the IFN‐based treatment group, OS time was significantly shorter for the programmed death‐ligand 1(PD‐L1)‐positive HCC than the PD‐L1‐negative HCC group (p = 0.0183). No significant difference was observed in the recurrence rate between PD‐L1‐positive and PD‐L1‐negative HCC groups. In the IFN‐based treatment group, the recurrence rate in the cluster of differentiation (CD) 8‐positive group was significantly lower than in the CD8‐negative group (p = 0.0292). There was no difference in OS time between the CD8‐positive and CD8‐negative groups. In the IFN‐free treatment group, PD‐L1 and CD8 were not associated with recurrence rate or OS.ConclusionsNo statistically significant differences were observed in recurrence or OS rate after HCC resection in the IFN‐free treatment group compared with the IFN‐based treatment group. In the IFN‐based treatment group, PD‐L1 and CD8 expression on cancer cells might be prognostic factors.

ABSTRACTBackgroundHepatitis C virus (HCV) infection is one of the leading causes of liver‐related diseases such as cirrhosis and hepatocellular carcinoma. Despite ongoing efforts, no effective vaccine has been developed to date due to the virus's high mutation rate and extensive genetic variability. This study aimed to determine the prevalence of HCV infection among family members of HCV‐positive index cases, within related risk factors in them. Additionally, the study evaluated the therapeutic efficacy of the combination drug Sovodak (sofosbuvir–daclatasvir) based on HCV genotype.MethodsThis study is a descriptive cross‐sectional study conducted on the families of individuals with Hepatitis C (12 people) within the Guilan cohort population. Twenty family members of HCV‐positive individuals were enrolled. Data were collected using structured questionnaires that included socio‐demographic and clinical information. Blood samples were drawn from each participant, and sera were separated for serological analysis. HCV antibody‐positive samples were assessed by HCV‐RNA detection. Subsequently, positive samples underwent HCV genotyping. Then, HCV‐positive individuals were referred in Phase 3 clinical trial with ID: NCT03200184. for treatment and follow‐up. Treatment consisted of Sovodak (a combination of sofosbuvir 400 mg and daclatasvir 60 mg). The clinical and diagnostic effectiveness of the treatment was evaluated 12 weeks after therapy initiation.ResultsOut of the total cases, two were HCV antibody positive, and one of them was a 13‐year‐old girl who tested positive for HCV RNA by PCR. Her genotype was 1a, which matched her mother's genotype. This patient was successfully treated with Sovodak. The post‐treatment HCV RNA results were negative, indicating a sustained virologic response (SVR = 12).ConclusionEvidence of intrafamilial transmission was observed in this study, its frequency was extremely low and statistically negligible. Shared household items, although seemingly unlikely, such as toothpaste, may serve as a potential route of transmission within families, independent of direct interpersonal contact.

Despite the transformative impact of direct-acting antivirals (DAAs) on hepatitis C control, acute/recent hepatitis C virus (HCV) infections continue to be diagnosed in contemporary clinical practice. We describe acute/recent HCV cases diagnosed at a tertiary hospital in Madrid among men who have sex with men (MSM), including people living with HIV (PLHIV) and pre-exposure prophylaxis (PrEP) users. We conducted a retrospective, single-centre descriptive study including acute/recent HCV cases reported between January 2023 and January 2025. Cases were defined by detectable HCV RNA following a previously negative HCV serology or after a cured HCV infection (reinfection). Chemsex was defined as intentional use of psychoactive substances in sexual contexts; slamsex as injecting drugs in sexual contexts. Patients initially managed with watchful waiting were reassessed at 12 weeks to assess spontaneous clearance. Ninety-two cases were included; median age was 43 years (IQR 36-52) and 24 (26.1%) were >50 years. In total, 91 out of 92 (98.9%) were MSM; 70 (76.1%) were PLHIV and 19 (20.7%) were PrEP users. Among 84 patients with genotype data, 55 (59.8%) had genotype 1a, 8 (8.7%) 1b, and 21 (22.8%) genotype 4. HCV RNA was >6 log in 41 (44.6%) and >7 log in 18 (19.6%). Chemsex was reported by 72 (78.3%); among them, 38 (52.8%) reported slamsex. Among those with available data, 17 out of 54 (31.5%) had another sexually transmitted infection. Watchful waiting was initially adopted in 73 (79.3%); 5 out of 73 (6.8%) achieved spontaneous clearance at 12 weeks. Of those observed, 68 (93.2%) initiated DAAs; 9 (9.8%) were treated at diagnosis. Ten (10.9%) were lost to follow-up before treatment initiation; sustained virological response was achieved in treated patients. Acute/recent HCV diagnoses occurred predominantly among MSM, including PLHIV and PrEP users, with frequent reporting of chemsex/slamsex. Low spontaneous clearance and losses before treatment initiation highlight the need for targeted HCV testing and linkage to care in HIV/PrEP and sexual health services, alongside harm reduction and substance use support.

ABSTRACTBackground & AimsSeveral clinical risk models have been proposed to stratify hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis C virus (HCV) after sustained virologic response (SVR). However, validation efforts have focused on monocentric or country‐specific cohorts, and it is unclear if clinical risk models can be broadly applied to global populations. We characterised regional variation in model performance for HCC risk stratification in post‐SVR patients.MethodsFour HCC clinical risk models (aMAP score, FIB‐4 index, GES score, and Toronto HCC risk index [THRI]) were analysed in six real‐world cohorts, which included 8796 post‐SVR patients from different geographic regions globally. Model discrimination was assessed using Harrel's c‐statistic index. HCC incidence rates were compared across low‐, intermediate‐, and high‐risk groups for each model.ResultsDistributions of patient characteristics and HCC incidence rates varied across geographic regions. Predictive performances of models were comparable within each cohort despite the model with the highest c‐statistics differing by regions. Performance was lower than those from original reports overall; c‐statistics of models across most regions remained below 0.70.ConclusionsThere remains a continued need to improve discrimination and calibration of clinical models to stratify HCC risk in post‐SVR patients. Accuracy of models may differ by geographic region, underscoring the importance of external validation to assess transportability of models and suggesting no single model can be universally applied.

Hepatitis B virus RNA levels and clinical characteristics of persistent viremia in HBsAg-positive patients undergoing nucleos(t)ide analog.

Low Alpha-Fetoprotein in Non-Viral Early-Stage Hepatocellular Carcinoma: Complementary Des-Gamma-Carboxyprothrombin.

Virologic failure (VF) in children living with HIV (CLHIV) remains challenging in sub-Saharan Africa, reaching alarming rates in Cameroon. We sought to evaluate predictors of virologic response and HIV drug resistance (HIVDR) among CLHIV in Cameroon during the introduction of pediatric dolutegravir (pDTG)-based antiretroviral therapy (ART). We conducted a facility-based longitudinal study from November 2022 through April 2023 among CLHIV (age 0-10 years) attending the Chantal BIYA Foundation's Mother and Child Centre in Yaoundé-Cameroon. Plasma viral load (PVL) and HIVDR were evaluated, with VF defined as 2 consecutive PVL ≥1000copies/mL under active adherence counseling/support. Overall, the 318 enrolled participants had a median (interquartile range) age of 8 (6-9) years and 162/318 (50.9%) girls. Most (299/318, 94.03%) received pDTG-based ART and mean ART duration was 5.6 ± 2.6 years. At enrollment, 37 (11.6%) children were virally unsuppressed (PVL≥1000copies/mL), with higher odds among children from rural areas ( P = 0.018) and among those reporting poor adherence ( P < 0.001). After active adherence counseling and support, 30/37 (81.1%) children were resampled after 1 month and 3 remained unsuppressed, indicating <1% (3/311) with VF overall. Among those experiencing VF, HIVDR mutations were found in <1% (2/311) children [L74V(1/3), K103N(1/3), M184V(2/3), P225H(1/3)]. Virologic response among children receiving pDTG-containing ART was strong in Cameroon. Combining robust ART regimens with active adherence support can advance sustained progress towards HIV elimination in children by 2030 in sub-Saharan Africa.

Chronic hepatitis delta (CHD) is the most severe form of viral hepatitis and is associated with accelerated progression to cirrhosis and liver failure. Bulevirtide has shown promising results in trials, but real-world data on its effectiveness, safety and impact on patient-reported outcomes (PROs) remain limited. To evaluate the effectiveness, safety, and PROs (quality-of life-QoL; adherence) of bulevirtide therapy in CHD patients undergoing a dedicated pharmacist-led patient-education program (PEP). A prospective observational study enrolled 31 consecutive CHD patients receiving bulevirtide 2 mg daily at a tertiary referral centre. Virological, biochemical and combined responses were assessed at weeks 24, 48 and 60. QoL (through EQ-5D-5L questionnaire), adherence (proportion of days covered), and adverse events were monitored during follow-up. Bulevirtide significantly reduced HDV-RNA by week 24 (p < 0.01), with further reductions at week 48 (p = 0.05) and 60 (p < 0.01). Liver tests improved significantly from baseline to week 24 (p < 0.01) and remained stable. Combined response was achieved in 43.7% of patients by week 60. QoL improved significantly (p = 0.03), and adherence was excellent (≥ 90%). Adverse events were mostly mild and transient. In real-world clinical practice, bulevirtide achieved sustained virological and biochemical improvements with favourable safety and quality-of-life outcomes, confirming its effectiveness in routine management of CHD. While the 60-week data (n = 16) are exploratory due to the sample size, these findings confirm its effectiveness and safety in routine management of CHD.

Despite the availability of curative, direct-acting antiviral therapy, hepatitis C virus elimination remains incomplete. Losses across the care cascade continue to limit impact, from initial diagnosis to sustained virologic response. Fewer than 1/3 of individuals ultimately achieve cure. These gaps reflect a delivery system that does not align with the population most affected, many of whom have inconsistent engagement with outpatient care. The emergency department is critical, but underused point of contact, where the burden of undiagnosed and untreated infection is high. This manuscript presents a practical framework for integrating HCV testing and treatment into emergency care within a new United States. It focuses on five domains. Point of care RNA testing allows confirmation of infection during the encounter, reducing delays that contribute to loss to follow up. Treatment initiation is simplified through standardised eligibility criteria and use of pan genomic regimens supported by electronic decision support. A focused safety screen addresses key exclusions, including hepatitis B coinfection, advanced liver disease, renal impairment, and relevant drug interactions. Policy and financial barriers are examined, including prior authorisation requirements, variation of Medicaid coverage, and access to discount pricing programmes. Post treatment follow up is restructured through decentralised approaches such as dried blood spot testing, telemedicine, and linkage to harm reduction services. Implementation will vary across institutions and regions. Regulatory requirements, payer policies, and staffing models remain important constraints. These challenges identify areas for targeted policy reform and prospective study. The emergency department is not traditionally designed for chronic disease management. However, for a curable infection concentrated among patients who rely on episodic care, it may represent the most effective point of intervention.

Identifying barriers to hepatitis C virus elimination in the era of direct-acting antivirals.

Hepatitis C virus (HCV) infection is highly prevalent in U.S. jails, yet access to curative direct-acting HCV therapy remains limited because of the inmate Medicaid exclusion rule. However, an innovative expansion of the AIDS Drug Assistance Program in California now supports HCV treatment for individuals experiencing incarceration who are living with HIV. We describe the implementation of this pilot program in the Los Angeles County Jail, including the formation of a multidisciplinary task force designed to rapidly identify, evaluate, and initiate treatment despite the unpredictable length of stay and other barriers. Enabling treatment delivery within jail constraints has been possible with program adaptations such as provision of remaining HCV medications at release, shortened regimens and use of early sustained virologic response. Although challenges remain-including lack of universal screening, no funding for treatment of HCV monoinfection, and limited post-release linkage to care-this pilot demonstrates that targeted policy innovation combined with an effective implementation team can expand access to lifesaving HCV care in carceral settings in a group at very high risk.

In Europe, most people with HIV-1(PWH) achieve virologic suppression with effective and well-tolerated antiretroviral therapies (ART). In this context, patient-reported outcomes (PRO) are increasingly important for evaluating ART benefits. This study aimed to describe treatment durability, satisfaction and quality of life (QoL) in virologically suppressed PWH switching to a doravirine-based regimen (PWH-DOR). DoraVIH was a national, multicentre, real-world cohort study with two phases: cross-sectional and prospective follow-up of PWH-DOR at 3 (M3) and 15-18 months (M15-18) post-switch. Durability of the doravirine-based regimen was recorded at both follow-up visits, and on-treatment virologic response at M3. QoL was assessed at baseline (D0) and M15-18 using the SF-36 questionnaire. Pre-switch patient satisfaction with treatment was assessed at D0 using the HIV Treatment Satisfaction Questionnaire (HIVTSQs), and post-switch at M3 and M15-18 using the HIVTSQc. Among 143 PWH-DORincluded (mean age 51.1 ± 10.6 years; 68% men), durability was 94% (131/140) at M3 and 83% (114/138) at M15-18. All participants receiving doravirine at M3 remained virologically suppressed. SF-36 scores showed no significant QoL change between D0 (72.6 ± 17.2) and M15-18 (73.0 ± 19.6). Pre-switch treatment satisfaction averaged 50.2 ± 9.6 (HIVTSQs score). Most PWH-DOR reported better satisfaction (HIVTSQc score >0): 90% at M3 (96/107) and 90% at M15-18 (89/99). Despite the absence of a control group and limited sample size, these real-world data support the effectiveness of switching to a doravirine-based regimen, with high durability and improved patient satisfaction.